Table 1.

Baseline Demographics of Each Enrolled Treatment Group

	Oral tenofovir	Tenofovir gel	HEC placebo gel
Participants enrolled	18	12	6
Age (years)
Mean (STD)	42.1 (11.4)	41.3 (11.9)	43.7 (10.2)
Gender
Male	14 (78%)	10 (83%)	4 (67%)
Female	4 (22%)	2 (17%)	2 (33%)
Latino or of Hispanic origin
Yes	5 (28%)	3 (25%)	2 (33%)
No	13 (72%)	9 (75%)	4 (67%)
Race
Asian	0	0	0
Black or African-American	2 (11%)	1 (8%)	1 (17%)
Native Hawaiian or Pacific Islander	0	0	0
White	15 (83%)	10 (84%)	5 (83%)
Other	1 (6%)	1 (8%)	0

HEC, hydroxyethyl cellulose; STD, standard deviation.